Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Anus Neoplasms, Astrocytoma, Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Ependymoma, Esophageal Neoplasms, Glioblastoma, Glioma, Carcinoma, Hepatocellular, Oligodendroglioma, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Neuroectodermal Tumors, Primitive, Esthesioneuroblastoma, Olfactory, Glioma, Subependymal, Gliosarcoma, Breast Neoplasms, Male

NCT00063895 2013-01-09

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck

Phase 1/2 Completed

80 enrolled

GynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung

NCT00130520 2012-05-28

Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer

Phase 2 Completed

40 enrolled 9 charts

Gynecologic

Ovarian Neoplasms

NCT00603356 2011-09-27

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Phase 1 Completed

60 enrolled

GastrointestinalGynecologicOther solid neoplasmSarcomaThoracic

Mesothelioma, Neoplasms, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

NCT00217529 2010-09-21

Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Phase 1/2 Completed

Gynecologic

Carcinoma, Ovarian Epithelial, Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

Clinical Trials

Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors

Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer

Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer

Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma

Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer

Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer

Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck

Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer